Altamira Therapeutics Ltd.
CYTOF
Altamira Therapeutics Ltd. is a biotechnology company focused on innovative therapies for unmet medical needs. The primary purpose of the company is to develop novel treatments in the field of tinnitus, hearing loss, and select other central nervous system and inner ear disorders. Its lead product candidate aims to address acute and chronic tinnitus through a nanoparticle-based delivery system, showing potential to revolutionize current therapeutic approaches. Additionally, Altamira is engaged in creating RNA delivery platforms, pushing boundaries in RNA therapeutics and advancing precision medicine applications. Notably impacting the healthcare and biotechnology sectors, the company also explores partnerships to expand its research capabilities and product reach. Based in Basel, Switzerland, Altamira Therapeutics Ltd. is strategically positioned within the European medical research scene, contributing to the global landscape of biotech innovation. Their commitment to addressing significant health issues reflects a forward-thinking approach in treating conditions with few existing solutions.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$8M
▼ -96.4% YoY
Op. Margin
–
ROIC
-74.30%
▼ -3.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$6M
▲ +51.5% YoY
Op. Cash Flow (TTM)
-$6M
▲ +52.3% YoY
Net Debt
-$638K
Net Cash Position
Cash & Equiv.
$999K
Continue Research
Peers
Biotechnology · Pick stocks to compare with CYTOF
Altamira Therapeutics (CYTOF) in three numbers
Questions about Altamira Therapeutics
Is Altamira Therapeutics a high-quality business?
Altamira Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$637571, and its weakest is return on capital at -74.3%. The Quality tab shows every check against its target.
Does Altamira Therapeutics (CYTOF) pay a dividend?
No. Altamira Therapeutics (CYTOF) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 19 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CYTOF
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.